Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis. 2025 Apr 30; 80(4):881-888.
-
Rodr?guez-L?pez ER, L?pez P, Rodr?guez Y, S?nchez R, Acevedo VS, Encarnaci?n J, Tirado G, Ortiz-S?nchez C, Mespl?de T, Rivera-Amill V. HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors' Phenotypic Susceptibility. AIDS Res Hum Retroviruses. 2025 Jan; 41(1):43-54.
-
Ochieng C, Chen JC, Osita MP, Katz LS, Griswold T, Omballa V, Ng'eno E, Ouma A, Wamola N, Opiyo C, Achieng L, Munywoki PK, Hendriksen RS, Freeman M, Mikoleit M, Juma B, Bigogo G, Mintz E, Verani JR, Hunsperger E, Carleton HA. Molecular characterization of circulating Salmonella Typhi strains in an urban informal settlement in Kenya. PLoS Negl Trop Dis. 2022 08; 16(8):e0010704.
-
Gong Y, Zhi K, Nagesh PKB, Sinha N, Chowdhury P, Chen H, Gorantla S, Yallapu MM, Kumar S. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia. Viruses. 2020 05 20; 12(5).
-
Gong Y, Chowdhury P, Nagesh PKB, Rahman MA, Zhi K, Yallapu MM, Kumar S. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep. 2020 03 02; 10(1):3835.
-
Gao C, Fan YL, Zhao F, Ren QC, Wu X, Chang L, Gao F. Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA). Eur J Med Chem. 2018 Sep 05; 157:1081-1095.
-
Wren C, Bell E, Eiland LS. Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018 12; 52(12):1233-1237.
-
Matsui T, Kodama T, Mori T, Tadakoshi T, Noguchi H, Abe I, Morita H. 2-Alkylquinolone alkaloid biosynthesis in the medicinal plant Evodia rutaecarpa involves collaboration of two novel type III polyketide synthases. J Biol Chem. 2017 06 02; 292(22):9117-9135.
-
Wang H, Silva AJ, Benitez JA. 3-Amino 1,8-naphthalimide, a structural analog of the anti-cholera drug virstatin inhibits chemically-biased swimming and swarming motility in vibrios. Microbes Infect. 2017 06; 19(6):370-375.
-
McPhillie M, Zhou Y, El Bissati K, Dubey J, Lorenzi H, Capper M, Lukens AK, Hickman M, Muench S, Verma SK, Weber CR, Wheeler K, Gordon J, Sanders J, Moulton H, Wang K, Kim TK, He Y, Santos T, Woods S, Lee P, Donkin D, Kim E, Fraczek L, Lykins J, Esaa F, Alibana-Clouser F, Dovgin S, Weiss L, Brasseur G, Wirth D, Kent M, Hood L, Meunieur B, Roberts CW, Hasnain SS, Antonyuk SV, Fishwick C, McLeod R. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016 07 14; 6:29179.